OSR Holdings Inc (OSRH) — Titan Protect Analysis

OSRH

OSR Holdings Inc

Healthcare · ·

$0.39

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$15M

Total market value of the company

Trailing P/E

14.13

Reasonably valued

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

-36.4%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-14.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+2477% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About OSR Holdings Inc

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L

https://www.osr-holdings.com

Country: United States Employees: 22 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.093

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1757

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.832

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-80.5%

Historical annualised return based on price data

Max Drawdown

-96.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.87

Less volatile than the market — more defensive

52W High

$1.79

78% below the year high

52W Low

$0.38

2% above the year low

Avg Volume

6,412,204

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.03

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.89

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

20.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-757.6%

Profit from core operations before interest and tax

Free Cash Flow

$1M

Positive — the business generates more cash than it spends

Revenue (TTM)

$3M

Total revenue over the last 12 months

Net Income

$-9,549,548

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$10.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go